American College of Rheumatology

Pfizer won't launch its second Remicade biosimilar in U.S.
Promising new treatments for plaque psoriasisThe American College of Rheumatology annual meeting wrapped this month in San Diego. Results from long-awaited safety trials show promising new treatments.
Nearly half of BCBS members discontinue this RA drug after 1 yearAnalysis from Prime shows that improvements in persistency, adherence is key in RA treatments.
Biosimilars need better labeling: PhysiciansIn FDA's 2012 Draft Guidance on Biosimilars, the Agency called for "labeling of a proposed product to include all the information necessary for a health professional to make prescribing decisions," including clear statements of a product's approval as a biosimilar to a reference product and whether or not it has been determined to be interchangeable.
ACR: Lesinurad as a combo therapy with allopurinol may be effective in treating goutData from 2 phase 3 studies of lesinurad in combination with allopurinol in gout patients was presented at the American College of Rheumatology (ACR) 2014 annual meeting in Boston.
Drugs in Perspective: Otezla (apremilast)Otezla (apremilast), a small-molecule inhibitor of phosphodiesterase 4 (PDE4), was approved by FDA on March 21, 2014, for the treatment of adult patients with active psoriatic arthritis. On September 23, 2014, it was approved for a second indication, the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy
Allopurinol alone found inadequate for gout controlAllopurinol, considered the standard of care for gout, may be inadequate to lower uric acid levels in patients with gout, according to new safety and efficacy data from a large study presented at the American College of Rheumatology 2013 annual meeting recently in San Diego, Calif.
Allopurinol alone found inadequate for gout controlAllopurinol, considered the standard of care for gout, may be inadequate to lower uric acid levels in patients with gout, according to new safety and efficacy data from a large study presented at the American College of Rheumatology (ACR) 2013 annual meeting recently in San Diego, Calif.
Updated guidelines for juvenile arthritisThe American College of Rheumatology (ACR) just updated its recommendations for the treatment of systemic juvenile idiopathic arthritis (JIA) and secondary tuberculosis screening among children receiving biologic medications.